Type 2 diabetes mellitus (T2D) contributes greatly to global morbidity and mortality,     and to the associated costs of treatment. Worldwide it is estimated that over 285 million adults have diabetes,and the cost of treatment in Australia alone is about $14.6 billion pa.

Failure to treat T2D can lead to nephropathy, angiopathy, heart disease, blindness, and death. Unfortunately, current treatments can have side effects including heart failure, liver disease, renal shutdown. It is therefore imperative that improved treatment options are found to lower blood glucose levels in people suffering T2D.

One attractive course of action to lower blood glucose is to attenuate gluconeogenesis. This study seeks to develop inhibitors to Fructose-1,6-Bisphosphatase (FBPase-1), a key gluconeogenic enzyme. A number of techniques will be used to determine the appropriate druggable sites of FBPase-1, including analytical ultracentrifugation (AUC), enzyme kinetics, in vitro mutagenesis, X-ray cystallography and molecular dynamics simulations.